Reata Pharmaceuticals Book Value 2011-2026 | RETA

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Reata Pharmaceuticals

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
514 M	735 M	858 M	257 M	15.2 M	-147 M	-215 M	-273 M	-274 M	-277 M	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
858 M	-277 M	119 M

Quarterly Book Value Reata Pharmaceuticals

2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
454 M	514 M	584 M	632 M	680 M	735 M	732 M	778 M	815 M	858 M	858 M	858 M	858 M	682 M	682 M	682 M	682 M	345 M	345 M	345 M	345 M	135 M	135 M	135 M	135 M	89.1 M	89.1 M	89.1 M	89.1 M	79 M	79 M	79 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
858 M	79 M	456 M

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	49 M	-	2.43 %	$ 254 M	Germany
I-Mab IMAB	5.63 B	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	253 M	-	-	$ 40.3 B	USA
Genfit SA GNFT	282 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	34.9 M	-	-13.47 %	$ 169 M	France
Midatech Pharma plc MTP	8.32 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	2.33 B	-	-1.52 %	$ 24.7 M	USA
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Adverum Biotechnologies ADVM	70.7 M	-	-	$ 86.2 M	USA
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
Applied Molecular Transport AMTI	60.8 M	-	-	$ 10.1 M	USA
Aeterna Zentaris AEZS	13.2 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	-37 K	-	-10.17 %	$ 12.2 K	USA
AIkido Pharma AIKI	69.4 M	-	1.93 %	$ 17.4 M	USA
Aeglea BioTherapeutics AGLE	715 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	29.5 M	-	-	$ 26.5 M	USA
Akero Therapeutics AKRO	750 M	-	-	$ 3.67 B	USA
Akouos AKUS	234 M	-	0.23 %	$ 488 M	USA
Институт стволовых клеток человека ISKJ	10.6 M	-	-	-	Russia
Allena Pharmaceuticals ALNA	18.9 M	-	3.16 %	$ 1.9 M	USA
Alpine Immune Sciences ALPN	179 M	-	-	$ 2.17 B	USA
Aileron Therapeutics ALRN	16.9 M	-	10.36 %	$ 9.8 M	USA
Aravive ARAV	10.7 M	-	-13.39 %	$ 1.45 M	USA
Aptose Biosciences APTO	-27.2 M	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	38.3 M	-	-39.0 %	$ 4.57 M	USA
CureVac N.V. CVAC	688 M	-	-	$ 867 M	Germany
AstraZeneca PLC AZN	48.7 B	-	-	$ 96.9 B	Britain
Avenue Therapeutics ATXI	1.83 M	-	-52.27 %	$ 4.45 M	USA
AVROBIO AVRO	94.7 M	-	1083.1 %	$ 745 M	USA
Axcella Health AXLA	4.16 M	-	-16.42 %	$ 249 M	USA
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel
BeiGene, Ltd. BGNE	4.36 B	-	0.49 %	$ 251 B	Cayman-islands
bluebird bio BLUE	195 M	-	-	$ 546 M	USA
Allakos ALLK	169 M	-	-	$ 28.6 M	USA
Brickell Biotech BBI	11.6 M	-	-5.38 %	$ 6.06 M	USA
Atreca BCEL	78.4 M	-	-11.76 %	$ 5.79 M	USA
CASI Pharmaceuticals CASI	108 M	-	-	$ 35.4 M	USA
Ampio Pharmaceuticals AMPE	3.36 M	-	-11.43 %	$ 502 K	USA
ChemoCentryx CCXI	286 M	-	-	$ 3.74 B	USA
AlloVir ALVR	78.8 M	-	4.14 %	$ 49.1 M	USA
Завод ДИОД DIOD	-243 M	-	-	-	Russia
Фармсинтез LIFE	29.8 B	-	-	-	Russia
Bellerophon Therapeutics BLPH	2.53 M	-	-74.18 %	$ 955 K	USA
Chimerix CMRX	193 M	-	-	$ 756 M	USA
Teligent, Inc. TLGT	5.17 B	-	-13.85 %	$ 16.1 M	USA
AbbVie ABBV	134 B	$ 208.7	-0.07 %	$ 369 B	USA
Calithera Biosciences CALA	49.1 M	-	-10.95 %	$ 876 K	USA
Cara Therapeutics CARA	20.9 M	-	-3.03 %	$ 260 M	USA
Viela Bio, Inc. VIE	424 M	-	-	$ 2.91 B	USA
AbCellera Biologics ABCL	967 M	$ 3.52	-0.14 %	$ 1.05 B	Canada